Datos Y Bibliografía
-
Notas
SLT. Criterios diagnósticos y estratificación de riesgo elevado.
SLT. Medidas generales de tratamiento.PSEUDOALTERACIONES RENALES en ONCOLOGÍA:
ESQUEMAS de TTº en ONCOLOGÍA (abreviaturas más utilizadas):
– ABVD: Doxorrubicina, bleomicina, vinblastina, dacarbazina.
– AC: Doxorrubicina y Ciclofosfamida.
– AC-T: Doxorrubicina, ciclofosfamida, paclitaxel.
– AIM: Doxorrubicina, ifosfamida, mesna.
– AL-SARRAF: Cisplatino, 5-fluoruracilo.
d
– AT: Doxorrubicina y docetaxel.– BEACOPP: Bleomicina, Etoposido, Doxorrubicina (Ariamicina), Ciclofosfamida, Vincristina, Procarbazina, Prednisona.
– BEP: Bleomicina, etopósido, cisplatino.
– BR: Bendamustina, rituximab.
– CAP: Ciclofosfamida, doxorrubicina, cisplatino.
– CAV: Ciclofosfamida, doxorrubicina, vincristina.
– CAPEOX: ver Xelox.
–CAPIRI: ver XELIRI
–CAPOX: ver XELOX
– CDDP-BCNU: cisplatino-carmustina.
– CHOP: Ciclofosfamida, doxorrubicina, vincristina, prednisona.
– CMF: ciclofosfamida, metotrexate, 5-flurouracilo.
–CMV: cisplatino, metotrexate, vimblastina.
– Coss 86: Doxorubicina, Metotrexate, Cisplatino, Ifosfamida, Mesna
– CYVADIC: ciclofosfamida, vincristina, doxorrubicina, dacarbacina.
– CVP: Ciclofosfamida, vincristina, prednisona.
– DCF: Docetaxel, cisplatino, 5-fluoruracilo.
– DCF modificado: Docetaxel, cisplatino, 5-fluoracilo, leucovorin.
– DHAP: Cisplatino, citarabina, dexametasona.
– EC: Epirrubicina, ciclofosfamida.
– ECF: Epirrubicina, cisplatino, 5 fluoruracilo.
– ECX: Epirrubicina, cisplatino, capecitabina.
– EMA-CO: Etoposido, metotrexate, actinomicina D, leucovorin , ciclofosfamida, vincristina.
– EMA-EP: Etoposido, metotrexate, actinomicina D/ etopósido, cisplatino.
– EOX: Epirrubicina, oxaliplatino, capecitabina.
– EP ó PE: Etoposido, cisplatino.
– EPOCH: Etopósido,prednisona, vincristina, ciclofosfamida, doxorrubicina.
– ESHAP: Etopósido, cisplatino, citarabina, metilprednisolona.
– EXTREME: Cisplatino ( o carboplatino), 5-fluorouracilo, cetuximab.
– FAC: 5 flurouracilo, doxorrubicina, ciclofosfamida.
– FEC: 5-fluorouracilo, ciclofosfamida.
– FLOX: 5-fluorouracilo, leucovorin, oxaliplatino.
– FOLFIRI: 5-fluorouracilo, leucovorin, irinotecán.
– FOLFIRINOX: 5-fluorouracilo, leucovorin, irinotecán, oxaliplatino.
– FOLFOX: 5-fluorouracilo, leucovorin, oxaliplatino.
– FOLFOXIRI: 5-fluorouracilo, leucovorin, oxaliplatino, irinotecán.
– FLOT: Docetaxel, oxaliplatino, leucovorin, 5-fluorouracilo.
– FR: Fludarabina, rituximab.
– GEMCAP: Gemcitabina, capecitabina.
– GC: Gemcitabina, cisplatino.
–GEMER: Gemcitabina, erlotinib.
– GEMOX: Gemcitabina, oxaliplatino.
– GT: Gemcitabina, paclitaxel.
– HYPERCVAD: Ciclofosfamida, vincristina, adriamicina, dexametasona, metotrexate, citarabina
– ICE: Ifosfamida, carboplatino, etopósido.
– ID: Ifosfamida, doxorrubicina.
– IE: Ifosfamida, etoposido.
– IFL: Irinotecan, 5-fluorouracilo, leucovorin.
– IROX: Irinotecan, oxaliplatino.
– IVA: Ifosfamida, vincristina, actinomicina.
– MACOP-B: Metotrexato, Doxorrubicina (Adriamicina), Ciclofosfamida, Vincristina, Prednisona, Bleomicina.
– MAID: Mesna, Doxorrubicina, ifosfamida, dacarbacina.
– MAP: Metotrexate, doxorrubicina, cisplatin.
– MVAC: Metotrexate, vinblastina, doxorrubicina, cisplatino.
– PCV: Procarbazina, lomustina, vincristina.
– Regimen Roswell Park: 5-Fluorouracilo, leucovorina, capecitabina.
– R-CHOP: Rituximab, ciclofosfamida, doxorrubicina, vincristina, prednisona.
– R-CVP: Rituximab, ciclofosfamida, vincristina, prednisona.
– R-FC: Rituximab, fludarabina, ciclofosfamida.
– R-ICE: Rituximab, ifosfamida, carboplatino, etopósido.
– SMILE: dexametasona, metotrexato, ifosfamida, L- asparaginasa y etopósido.
– TAC: Doxorrubicina, ciclofosfamida, docetaxel.
– TC: Docetaxel, ciclofosfamida.
– TCH: Docetaxel, carboplatino, trastuzumab.
– TH: Paclitaxel, trastuzumab.
– TIP: Paclitaxel, ifosfamida, cisplatino.
– THP: Docetaxel, trastuzumab, pertuzumab
– TPEx: Cisplatino, docetaxel, cetuximab.
– TPF: Cisplatino, docetaxel, 5-fluorouracilo.
– VAC ó VAdriaC: Vincristina, adriamicina (doxorrubicina), ciclofosfamida.
– VAC-VI: Vincristina, adriamicina, ciclofosfamida + vincristina/irinotecan.
– VAD: Vincristina, doxorrubicina, dexametasona.
– VeIP: Vinblastina, ifosfamida, cisplatino.
– VELP: Vinblastina, ifosfamida, cisplatino, topotecan.
– VIP: Etopósido, ifosfamida, cisplatino.
– VRd: Bortezomib, lenalinomida, dexametasona
– VTd: Bortezomib, talidomida, dexametasona
– XELIRI: Capecitabina, irinotecan.
– XELOX: Oxaliplatino, capecitabina.
-
Bibliografía general con utilidad en distintos grupos de fármacos
Shepherd R, Harrap KR. Modulation of the toxicity and antitumour activity of alkylating drugs by steroids. Br J Cancer. 1982 Mar;45(3):413-20. doi: 10.1038/bjc.1982.69. PMID: 7073935; PMCID: PMC2010934.
Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001 Jan;24(1):19-38. doi: 10.2165/00002018-200124010-00003. PMID: 11219485.
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008 Jun 1;26(16):2767-78. doi: 10.1200/JCO.2007.15.0177. Erratum in: J Clin Oncol. 2010 Feb 1;28(4):708. PMID: 18509186.
Seiter K. Toxicity of the topoisomerase I inhibitors. Expert Opin Drug Saf. 2005 Jan;4(1):45-53. doi: 10.1517/14740338.4.1.45. PMID: 15709897.
Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010 May;149(4):578-86. doi: 10.1111/j.1365-2141.2010.08143.x. Epub 2010 Mar 16. PMID: 20331465.
Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Rodriguez-Pascual J, Cheng E, Maroto P, Duran I.Anticancer Drugs. 2010 Jun;21(5):478-86. doi: 10.1097/cad.0b013e32833760bf.PMID: 20401967
Massard C, Patard JJ, Hermine O, Ravaud A. Gestion des effets secondaires des thérapies ciblées dans le cancer du rein: effets secondaires iatrogéniques [Management of side effects of targeted therapies in renal cancer: iatrogenic side effects]. Bull Cancer. 2011;98(3 Suppl):S79-94. French. doi: 10.1684/bdc.2011.1447. PMID: 25819130.
Wendorff TJ, Schmidt BH, Heslop P, Austin CA, Berger JM. The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol. 2012 Dec 7;424(3-4):109-24. doi: 10.1016/j.jmb.2012.07.014. Epub 2012 Jul 25. PMID: 22841979; PMCID: PMC3584591.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239. PMID: 22437870; PMCID: PMC4856023.
Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013 Jul-Aug;63(4):249-79. doi: 10.3322/caac.21184. Epub 2013 May 28. PMID: 23716430.
Jhaveri KD, Fishbane S. Nephrology Crossword: Onco-nephrology--chemotherapy agents and nephrotoxicity. Kidney Int. 2013 Aug;84(2):421-2. doi: 10.1038/ki.2013.50. PMID: 23903433.
Glomerular diseases associated with cancer, chemotherapy,and hematopoietic stem cell transplantation. Jhaveri KD, Shah HH, Patel C, Kadiyala A, Stokes MB, Radhakrishnan J.Adv Chronic Kidney Dis. 2014 Jan;21(1):48-55. doi: 10.1053/j.ackd.2013.08.003.PMID: 24359986
Wang Q, Qi Y, Zhang D, Gong C, Yao A, Xiao Y, Yang J, Zhou F, Zhou Y. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol. 2015 May;36(5):3471-82. doi: 10.1007/s13277-014-2983-9. Epub 2014 Dec 28. PMID: 25542231; PMCID: PMC4445483.
Drug-induced glomerular disease: direct cellular injury. Markowitz GS, Bomback AS, Perazella MA.Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1291-9. doi: 10.2215/CJN.00860115. Epub 2015 Apr 10.PMID: 25862776
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, Cornell LD, Feldman P, Stokes MB, Zapata SA, Hodi FS, Ott PA, Yamashita M, Leaf DE.Kidney Int. 2016 Sep;90(3):638-47. doi: 10.1016/j.kint.2016.04.008. Epub 2016 Jun 7.PMID: 27282937
Liamis G. Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol. 2016. PMID: 26939882.
Jhaveri KD. Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System. Kidney Int. 2016
Jhaveri KD. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. KI Rep. 2016. PMID: 29318210; PMCID: PMC5720524.
Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med. 2016 Jul;4(14):272. doi: 10.21037/atm.2016.07.10. PMID: 27563659; PMCID: PMC4971373.
Belliere J, Meyer N, Mazieres J, Ollier S, Boulinguez S, Delas A, Ribes D, Faguer S. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer. 2016 Dec 6;115(12):1457-1461. doi: 10.1038/bjc.2016.358. Epub 2016 Nov 10. PMID: 27832664; PMCID: PMC5155358.
Izzedine H, El-Fekih RK, Perazella MA. The renal effects of ALK inhibitors. Invest New Drugs. 2016 Oct;34(5):643-9. doi: 10.1007/s10637-016-0379-y. Epub 2016 Jul 29. PMID: 27468827.
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, Launay-Vacher V, Jhaveri KD; Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors.Am J Nephrol. 2017;45(2):160-169. doi: 10.1159/000455014. Epub 2017 Jan 12.PMID: 28076863
Moledina DG, Perazella MA. Drug-Induced Acute Interstitial Nephritis. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2046-2049. doi: 10.2215/CJN.07630717. Epub 2017 Sep 11. PMID: 28893923; PMCID: PMC5718279.
Wanchoo R, Abudayyeh A, Doshi M, Edeani A, Glezerman IG, Monga D, Rosner M, Jhaveri KD. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clin J Am Soc Nephrol. 2017 Jan 6;12(1):176-189. doi: 10.2215/CJN.06100616. Epub 2016 Sep 21. PMID: 27654928; PMCID: PMC5220662.
El Bitar S, Weerasinghe C, El-Charabaty E, Odaimi M. Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy. Case Rep Oncol Med. 2018 Jan 31;2018:8408015. doi: 10.1155/2018/8408015. PMID: 29666732; PMCID: PMC5831873.
Kidney Complications of Immune Checkpoint Inhibitors: A Review. Shingarev R, Glezerman IG.Am J Kidney Dis. 2019 Oct;74(4):529-537. doi: 10.1053/j.ajkd.2019.03.433. Epub 2019 Jul 11.PMID: 31303350
de Francisco ALM, Macía M, Alonso F, García P, Gutierrez E, Quintana LF, Quiroga B, Torregrosa I. Onco-Nephrology: Cancer, chemotherapy and kidney. Nefrologia (Engl Ed). 2019 Sep-Oct;39(5):473-481. English, Spanish. doi: 10.1016/j.nefro.2018.10.016. Epub 2019 Mar 29. PMID: 30929891.
Renal Vasculitis and Pauciimmune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.Gallan AJ, Alexander E, Reid P, Kutuby F, Chang A, Henriksen KJ.Am J Kidney Dis. 2019 Dec;74(6):853-856. doi: 10.1053/j.ajkd.2019.04.016. Epub 2019 Jun 14.PMID: 31204194
Moliz C, Cavero T, Morales E, Gutiérrez E, Alonso M, Praga M. Renal damage secondary to check-point inhibitors. Nefrologia (Engl Ed). 2020 Mar- Apr;40(2):206-208. English, Spanish. doi: 10.1016/j.nefro.2019.05.004. Epub 2019 Oct 12. PMID: 31615688.
Charmetant X, Teuma C, Lake J, Dijoud F, Frochot V, Deeb A. A new expression of immune checkpoint inhibitors' renal toxicity: when distal tubular acidosis precedes creatinine elevation. Clin Kidney J. 2019 May 14;13(1):42-45. doi: 10.1093/ckj/sfz051. PMID: 32082551; PMCID: PMC7025331.
Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer. 2020 Jan;30(1):89-93. doi: 10.1136/ijgc-2019-000714. Epub 2019 Dec 1. PMID: 31792084.
Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Oleas D, Bolufer M, Agraz I, Felip E, Muñoz E, Gabaldón A, Bury R, Espinel E, Serón D, García-Carro C, Soler MJ.Clin Kidney J. 2020 Feb 10;14(5):1364-1370. doi: 10.1093/ckj/sfaa008. eCollection 2021 May.PMID: 34221369
Kitchlu A, Jhaveri KD, Wadhwani S, Deshpande P, Harel Z, Kishibe T, Henriksen K, Wanchoo R. A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. Kidney Int Rep. 2020 Oct 16;6(1):66-77. doi: 10.1016/j.ekir.2020.10.002. PMID: 33426386; PMCID: PMC7783581.
Verzicco I, Regolisti G, Quaini F, Bocchi P, Brusasco I, Ferrari M, Passeri G, Cannone V, Coghi P, Fiaccadori E, Vignali A, Volpi R, Cabassi A. Electrolyte Disorders Induced by Antineoplastic Drugs. Front Oncol. 2020 May 19;10:779. doi: 10.3389/fonc.2020.00779. PMID: 32509580; PMCID: PMC7248368.
Kitchlu A, Jhaveri KD, Wadhwani S, Deshpande P, Harel Z, Kishibe T, Henriksen K, Wanchoo R. A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. Kidney Int Rep. 2020 Oct 16;6(1):66-77. doi: 10.1016/j.ekir.2020.10.002. PMID: 33426386; PMCID: PMC7783581.
Herrmann SM, Alexander MP, Romero MF, Zand L. Renal Tubular Acidosis and Immune Checkpoint Inhibitor Therapy: An Immune-Related Adverse Event of PD-1 Inhibitor-A Report of 3 Cases. Kidney Med. 2020 Aug 11;2(5):657-662. doi: 10.1016/j.xkme.2020.05.015. PMID: 33089143; PMCID: PMC7568062.
The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage. Kwiatkowska E, Domański L, Dziedziejko V, Kajdy A, Stefańska K, Kwiatkowski S.Int J Mol Sci. 2021 Jun 6;22(11):6109. doi: 10.3390/ijms22116109.PMID: 34204029
Kitchlu A, Jhaveri KD, Sprangers B, Yanagita M, Wanchoo R. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. Clin Kidney J. 2021 May 8;14(9):2012-2022. doi: 10.1093/ckj/sfab090. PMID: 34476087; PMCID: PMC8406068.
Workeneh BT, Jhaveri KD, Rondon-Berrios H. Hyponatremia in the cancer patient. Kidney Int. 2020 Oct;98(4):870-882. doi: 10.1016/j.kint.2020.05.015. Epub 2020 Jun 1. PMID: 32497528.
Gudsoorkar P, Sise ME, Jhaveri KD. Onconephrology: The Growth of Cancer- Kidney Connection. Adv Chronic Kidney Dis. 2021 Sep;28(5):391-393. doi: 10.1053/j.ackd.2021.12.003. PMID: 35190105.
Gudsoorkar P, Langote A, Vaidya P, Meraz-Muñoz AY. Acute Kidney Injury in Patients With Cancer: A Review of Onconephrology. Adv Chronic Kidney Dis. 2021 Sep;28(5):394-401.e1. doi: 10.1053/j.ackd.2021.09.008. PMID: 35190106.
Gupta S, Portales-Castillo I, Daher A, Kitchlu A. Conventional Chemotherapy Nephrotoxicity. Adv Chronic Kidney Dis. 2021 Sep;28(5):402-414.e1. doi: 10.1053/j.ackd.2021.08.001. PMID: 35190107.
Kala J, Salman LA, Geara AS, Izzedine H. Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents. Adv Chronic Kidney Dis. 2021 Sep;28(5):415-428.e1. doi: 10.1053/j.ackd.2021.09.003. PMID: 35190108.
Pelletier K, Škrtić M, Kitchlu A. Cancer therapy-induced hyponatremia: A case-illustrated reviewJ Oncol-Nephrol 2021;5(1):70-78.
Manohar S, Jhaveri KD, Perazella MA. Immunotherapy-Related Acute Kidney Injury. Adv Chronic Kidney Dis. 2021 Sep;28(5):429-437.e1. doi: 10.1053/j.ackd.2021.07.006. PMID: 35190109.
Barbar T, Jaffer Sathick I. Tumor Lysis Syndrome. Adv Chronic Kidney Dis. 2021 Sep;28(5):438-446.e1. doi: 10.1053/j.ackd.2021.09.007. PMID: 35190110.
Rosner MH, DeMauro Renaghan A. Disorders of Divalent Ions (Magnesium, Calcium, and Phosphorous) in Patients With Cancer. Adv Chronic Kidney Dis. 2021 Sep;28(5):447-459.e1. doi: 10.1053/j.ackd.2021.09.005. PMID: 35190111.
Saly DL, Eswarappa MS, Street SE, Deshpande P. Renal Cell Cancer and Chronic Kidney Disease. Adv Chronic Kidney Dis. 2021 Sep;28(5):460-468.e1. doi: 10.1053/j.ackd.2021.10.008. PMID: 35190112.
Lee M, Wang Q, Wanchoo R, Eswarappa M, Deshpande P, Sise ME. Chronic Kidney Disease in Cancer Survivors. Adv Chronic Kidney Dis. 2021 Sep;28(5):469-476.e1. doi: 10.1053/j.ackd.2021.10.007. PMID: 35190113.
Valério P, Barreto JP, Ferreira H, Chuva T, Paiva A, Costa JM. Thrombotic microangiopathy in oncology - a review. Transl Oncol. 2021 Jul;14(7):101081. doi: 10.1016/j.tranon.2021.101081. Epub 2021 Apr 13. PMID: 33862523; PMCID: PMC8065296.
Gudsoorkar P, Ruf R, Adnani H, Safdar K, Sparks MA. Onco-hypertension: An Emerging Specialty. Adv Chronic Kidney Dis. 2021 Sep;28(5):477-489.e1. doi: 10.1053/j.ackd.2021.09.011. PMID: 35190114.
Stotter BR, Chan C, Chanchlani R. Late Kidney Effects of Childhood Cancer and Cancer Therapies. Adv Chronic Kidney Dis. 2021 Sep;28(5):490-501.e1. doi: 10.1053/j.ackd.2021.09.001. PMID: 35190115.
Shirazian S, Starakiewicz P, Latcha S. Cancer Screening in End-Stage Kidney Disease. Adv Chronic Kidney Dis. 2021 Sep;28(5):502-508.e1. doi: 10.1053/j.ackd.2021.09.006. PMID: 35190116.
Ratanasrimetha P, Workeneh BT, Seethapathy H. Sodium and Potassium Dysregulation in the Patient With Cancer. Adv Chronic Kidney Dis. 2022 Mar;29(2):171-179.e1. doi: 10.1053/j.ackd.2022.01.003. PMID: 35817524.
Shirali AC, Sprangers B. Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. Adv Chronic Kidney Dis. 2022 Mar;29(2):208-216.e1. doi: 10.1053/j.ackd.2021.12.002. PMID: 35817528
Sandhu G, Adattini J, Armstrong Gordon E, O’Neill N. On behalf of the ADDIKD Guideline Working Group. International consensus guideline on anticancer drug dosing in kidney dysfunction. 2022. eviQ, Cancer Institute NSW. St Leonards, Australia
Uppal NN, Workeneh BT, Rondon-Berrios H, Jhaveri KD. Electrolyte and Acid- Base Disorders Associated with Cancer Immunotherapy. Clin J Am Soc Nephrol. 2022 Jun;17(6):922-933. doi: 10.2215/CJN.14671121. Epub 2022 Jan 21. PMID: 35063968; PMCID: PMC9269647.
Bharati J, Lahoud OB, Jhaveri KD, Izzedine H. AA Amyloidosis associated with cancers. Nephrol Dial Transplant. 2022 Jul 22:gfac217. doi: 10.1093/ndt/gfac217. Epub ahead of print. PMID: 35867878.
Gupta S, Gudsoorkar P, Jhaveri KD. Acute Kidney Injury in Critically Ill Patients with Cancer. Clin J Am Soc Nephrol. 2022 Mar 25;17(9):1385–98. doi: 10.2215/CJN.15681221. Epub ahead of print. PMID: 35338071; PMCID: PMC9625110.
Documento "Efectos renales adversos por Inhibidores del Check Point (ICP) en pacientes con cáncer. Recomendaciones del grupo Onconefrología de la S.E.N." (Ref. NEFRO-S-22-00526)
Mehmet Kanbay, Sidar Copur, Dimitrie Siriopol, Abdullah Burak Yildiz, Metehan Berkkan, Raluca Popa, Nuri Baris Hasbal, Alberto Ortiz, Mark A Perazella, The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis, Clinical Kidney Journal, 2022, sfac194, https://doi.org/10.1093/ckj/sfac194
Kanduri SR, Kovvuru K, Wickman TJ, Velez JCQ. A case of tumor-induced osteomalacia masked by acute kidney injury. Journal of Onco-Nephrology. 2022;0(0). doi:10.1177/23993693221134954
Chowdhury R, Turcotte AE, Rondon-Berrios H, Workeneh BT. Spurious Electrolyte and Acid-Base Disorders in the Patient With Cancer: A Review. Am J Kidney Dis. 2023 Mar 9:S0272-6386(23)00560-7. doi: 10.1053/j.ajkd.2023.01.441. Epub ahead of print. PMID: 36906215.